Except for ACSBG2, MAPK9, PIK3R3, and SREBF1, the remaining genes in the LMRS model exhibited no significant expression variations in the whole TCGA-HNSCC patient cohort, which could be attributed to the diverse treatments undertaken by each patient. This evidence concerns the gene ACSBG2 and head and neck squamous cell carcinoma.